Sepracor Insomnia Spot Suggests Lunesta “Product And Use” Ads Coming Soon
This article was originally published in The Pink Sheet Daily
Executive Summary
The unbranded spot tells patients suffering from insomnia to stay tuned for more information coming April 24 about “something on its way that could change your nights.” The ad first aired April 10. Sepracor is also planning to discuss labeling revisions with FDA based on its second six-month trial.
You may also be interested in...
Lunesta Has "Encouraging" Debut, Sepracor Says
For the week ending April 15, the insomnia agent brought in 21,381 new scripts, resulting in a 5.1% market share, Sepracor said. "It looks like…the principal new Rxs are coming from [Sanofi-Aventis'] Ambien," the company said. Sepracor is planning to pursue labeling adaptations to increase Lunesta's market potential.
Sepracor's "Product And Use" Lunesta Ad To Be "Very Visible," Company Says
Sepracor's Lunesta (eszopiclone) "product and use" ad campaign will "be very visible going forward," the company said during its April 25 earnings call
Lunesta Has "Encouraging" Debut, Sepracor Says
For the week ending April 15, the insomnia agent brought in 21,381 new scripts, resulting in a 5.1% market share, Sepracor said. "It looks like…the principal new Rxs are coming from [Sanofi-Aventis'] Ambien," the company said. Sepracor is planning to pursue labeling adaptations to increase Lunesta's market potential.